Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02220829 |
|
Recruitment Status :
Recruiting
First Posted : August 20, 2014
Last Update Posted : October 20, 2020
|
Sponsor:
Sir Mortimer B. Davis - Jewish General Hospital
Information provided by (Responsible Party):
Dr. Tamim Niazi, Sir Mortimer B. Davis - Jewish General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Approximately 50%-95% of prostate cancer patients undergoing radiation therapy (RT) develop symptomatic urinary problems .These symptoms can significantly diminish a patient's quality of life during and shortly after therapy. Alpha1-blockers, such as Rapaflo, act to decrease resistance to urinary flow.
This multi-institutional phase III trial is designed to compare standard of care versus preventive treatment with Rapaflo for prostate cancer patients, regardless of risk group, whose treatment consists of radical radiation therapy. We plan to recruit 188 patients across Quebec who will be randomized into two arms: rapaflo prescribed at start of radiation therapy or if/when symptoms appear.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Urinary Problems Prostate Cancer | Drug: Preventive administration of Rapaflo Drug: Standard Care | Phase 3 |
The efficacy of Rapaflo treatment will be assessed using the International Prostate Symptom Score (IPSS). The IPSS will be assessed at baseline before RT, 4 weeks into RT, the last day of RT, and monthly thereafter for a total duration of 6 months from start of RT. Patients will have 2 more IPSS assessments at 9 and 12 months. The total duration of follow-up will be one year from start of RT. We will compare the rate of IPSS increase in the Rapaflo group compared to the standard arm at different time point (4 weeks, 6 weeks and at the end of treatment). We will also determine the rate of IPSS return to baseline at 4 and 12 weeks after the end of treatment. The rate of therapy dependence in the 2 arms will be evaluated at 20 and 26 weeks.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 188 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Supportive Care |
| Official Title: | Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII). |
| Actual Study Start Date : | June 2016 |
| Estimated Primary Completion Date : | June 2021 |
| Estimated Study Completion Date : | December 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Prostate cancer
MedlinePlus related topics:
Prostate Cancer
Drug Information available for:
Silodosin
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Preventive administration of Rapaflo
Rapaflo treatment will start on day one of radiation therapy (early administration- before symptoms onset) and continue for a total duration of 6 months: 8 mg daily during 4 months and 8 mg every other day for 2 months.
|
Drug: Preventive administration of Rapaflo
Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
Other Names:
|
|
Standard care
Administration of alpha-blocker Rapaflo at the onset of symptomatic urinary problems caused by radiation therapy. 8 mg of Rapaflo is administered daily until disappearance of symptoms.
|
Drug: Standard Care
Administration of alpha-blocker Rapaflo only at onset of symptoms.
Other Names:
|
Primary Outcome Measures :
- To determine the rate of increase and the mean difference from the baseline IPSS score in the alpha-blocker (Rapaflo) group compared to the standard arm. [ Time Frame: IPSS will be assessed before radiation therapy (RT), 4 weeks into RT, the last day of RT, and monthly for first 6 months and also at 9 and 12 months from the start of RT. ]
Secondary Outcome Measures :
- To determine the rate of IPSS return to baseline, in the alpha-blocker (Rapaflo) group compared to the standard after the end of radiation treatment. [ Time Frame: IPSS score will be assessed at before radiation therapy (RT), at 4 and 12 weeks after the end of RT. ]
- To determine the rate of therapy dependence in both groups. [ Time Frame: At 3 and 6 months from start of radiation therapy. ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult male 18 years of age or older
- Patients with confirmed diagnosis of adenocarcinoma of the prostate.
- The primary treatment should be external beam radiation therapy (EBRT) with or without high dose rate (HDR) brachytherapy boost.
- Clinical or radiological diagnosis of T1a - T3b.
- No limitation with respect to Gleason score.
- No limitation with respect to total Prostate-specific Antigen (PSA) value.
- Karnofsky performance score (KPS) of ≥ 70.
Exclusion Criteria:
- Small cell cancer of the prostate
- T4 disease, invading bladder or rectum.
- Adjuvant or salvage radiation therapy
- Brachy monotherapy
- KPS < 70
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02220829
Contacts
| Contact: Ashley Feng, M.Sc. | 514-340-8222 ext 26510 | yanqi.feng.ccomtl@ssss.gouv.qc.ca |
Locations
| Canada, Quebec | |
| Jewish General Hospital, McGill University | Recruiting |
| Montréal, Quebec, Canada, H3T 1E2 | |
| Contact: Ashley Feng, M.Sc 514-340-8222 ext 26510 yanqi.feng.ccomtl@ssss.gouv.qc.ca | |
| Principal Investigator: Tamim Niazi, MD | |
Sponsors and Collaborators
Sir Mortimer B. Davis - Jewish General Hospital
Investigators
| Principal Investigator: | Tamim Niazi, MD | Jewish General Hospital, McGill University |
Publications of Results:
| Responsible Party: | Dr. Tamim Niazi, Radiation Oncologist, Sir Mortimer B. Davis - Jewish General Hospital |
| ClinicalTrials.gov Identifier: | NCT02220829 |
| Other Study ID Numbers: |
PCS VII |
| First Posted: | August 20, 2014 Key Record Dates |
| Last Update Posted: | October 20, 2020 |
| Last Verified: | October 2020 |
Keywords provided by Dr. Tamim Niazi, Sir Mortimer B. Davis - Jewish General Hospital:
|
alpha-blocker symptomatic urinary problems radiation therapy prostate cancer |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Prostatic Diseases Silodosin Adrenergic alpha-1 Receptor Antagonists |
Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents |